# Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer

> **NCT01113970** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Alaunos Therapeutics** · enrollment: 60 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Indibulin

## Key facts

- **NCT ID:** NCT01113970
- **Lead sponsor:** Alaunos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-03
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2013-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01113970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01113970, "Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01113970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*